Novavax (NVAX) investor relations material

Strategic transformation and partnerships

• Transitioned from a COVID-only focus to out-licensing technology and expanding into oncology and other infectious diseases.

• Secured major partnerships with Sanofi and Pfizer, with Sanofi launching NUVAXOVID and Pfizer selecting a first field for Matrix-M.

• Sanofi's launch includes direct-to-consumer campaigns and aims for significant U.S. and global market share growth in the coming months.

• Anticipates $200 million in near-term milestones from Sanofi, extending cash runway into the 2030s.

• Pfizer partnership includes up to $500 million in milestones and royalties for two decades per field.

Product development and clinical pipeline

• Matrix-M technology is being explored in oncology, with preclinical data from both internal and top pharma partners expected in the coming quarters.

• C. difficile vaccine asset could enter the clinic as early as 2027, targeting a multi-billion dollar market with a differentiated pentavalent approach.

• Lean R&D strategy with rigorous assessment filters and significant cost reductions, focusing on high-probability, high-need targets.

• Flexibility to partner or advance assets further based on value inflection points and financial strategy.

Market outlook and commercialization

• COVID and flu vaccine markets are converging, representing the largest combined vaccine opportunity, with Sanofi well-positioned due to strong tolerability data and market share in flu.

• NUVAXOVID is now being stocked in major U.S. pharmacies, with the bulk of the season's uptake expected over the next 8–10 weeks.

• Sanofi's approach is methodical, aiming for steady market share growth and global expansion, including launches in Canada, Germany, and Sweden.

• Direct-to-consumer campaigns and digital marketing are key to driving patient choice and uptake, leveraging NUVAXOVID's favorable tolerability profile.